english.prescrire.org > Prescrire International > N°133 - December 2012

n°133

December 2012

Issue Contents
Editorial

Free  Think about drug packaging

p.284
Frequently overlooked by industry and regulators

New Products


Adjuvant trastuzumab for breast cancer (A Second Look)

p.285-287
Longer follow-up confirms improved overall survival

Vemurafenib (New Drug)

p.288-290
Value unclear in metastatic melanoma

Sodium oxybate: not authorised for fibromyalgia (Regulation)

p.290
Thankfully!

Free  Herpes zoster vaccine (New Drug)

p.291
Not very effective in those who need it most

Estradiol + nomegestrol (New Combination)

p.292-293
Oral contraceptive claimed to be more natural, but presenting no obvious advantages

INN common stem: -gatran

p.293

Adverse Effects


Grapefruit and drug interactions

p.294-298

Organic anion or cation transport and drug interactions

p.296-297

Families of hospitalised children report errors accurately

p.298
Parent empowerment

Reviews


Immunoassay-based screening for colorectal cancer

p.299-302
More colonoscopies performed and more cancers detected than with Haemoccult°

Colorectal cancer screening: the situation in France in early 2012

p.301

Medical abortions in adolescent girls

p.303
No greater complication rate

Furosemide in acute decompensated heart failure

p.303
No difference between continuous infusion and 12-hourly injection

Outlook


Intention to treat analysis and per protocol analysis: complementary information

p.304-306

"Modified" intention to treat analysis

p.305

Free  Neuroscience: reporting bias

p.306
Risk of overmedication and adverse drug reactions

Free  Essential drugs: a concept that remains as relevant as ever

p.307
Back to basics

Masthead


Free  Masthead

p.282

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe